Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| 1 |
Eli Lilly
LLY
|
+$788M |
| 2 |
Uber
UBER
|
+$600M |
| 3 |
Netflix
NFLX
|
+$441M |
| 4 |
Goldman Sachs
GS
|
+$414M |
| 5 |
Microsoft
MSFT
|
+$412M |
Top Sells
| 1 |
Intuitive Surgical
ISRG
|
+$786M |
| 2 |
Nike
NKE
|
+$750M |
| 3 |
Walt Disney
DIS
|
+$743M |
| 4 |
Edwards Lifesciences
EW
|
+$702M |
| 5 |
Illumina
ILMN
|
+$618M |
Sector Composition
| 1 | Technology | 30.69% |
| 2 | Consumer Discretionary | 19.06% |
| 3 | Healthcare | 13.05% |
| 4 | Communication Services | 12.23% |
| 5 | Financials | 10.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
351
Pentair
PNR
$17.9B
| $8.19M | 0.01% |
275,249
+118,933
| +76% | +$3.54M |
|
352
First Foundation Inc
FFWM
$487M
| $8.03M | 0.01% |
785,212
+205,106
| +35% | +$2.1M |
|
353
JELD-WEN Holding
JELD
$537M
| $7.95M | 0.01% |
816,886
-51,301
| -6% | -$499K |
|
354
EOG Resources
EOG
$65.7B
| $7.89M | 0.01% |
219,678
-23,585
| -10% | -$847K |
|
355
Sandstorm Gold
SAND
$3.4B
| $7.86M | 0.01% |
1,569,629
-12,522
| -0.8% | -$62.7K |
|
|
CXO
356
DELISTED
CONCHO RESOURCES INC.
CXO
| $7.76M | 0.01% |
181,187
+1,896
| +1% | +$81.2K |
|
357
Denali Therapeutics
DNLI
$2.14B
| $7.69M | 0.01% |
+438,879
| New | +$7.69M |
|
358
Stoneridge
SRI
$229M
| $7.5M | 0.01% |
447,927
+142,660
| +47% | +$2.39M |
|
359
Oneok
OKE
$46.2B
| $7.49M | 0.01% |
343,457
-1,622,505
| -83% | -$35.4M |
|
360
iRhythm Technologies
IRTC
$5.85B
| $7.49M | 0.01% |
92,054
-62,727
| -41% | -$5.1M |
|
361
CRISPR Therapeutics
CRSP
$4.71B
| $7.49M | 0.01% |
+176,499
| New | +$7.49M |
|
362
Thermon Group Holdings
THR
$826M
| $7.46M | 0.01% |
494,722
+16,886
| +4% | +$254K |
|
363
Energy Transfer Partners
ET
$59.8B
| $7.41M | 0.01% |
1,610,348
-1,364,629
| -46% | -$6.28M |
|
364
Phreesia
PHR
$1.52B
| $7.39M | 0.01% |
351,429
-58,884
| -14% | -$1.24M |
|
365
ON Semiconductor
ON
$19.7B
| $7.35M | 0.01% |
+591,105
| New | +$7.35M |
|
366
Cytokinetics
CYTK
$6.22B
| $7.24M | 0.01% |
614,154
+4,190
| +0.7% | +$49.4K |
|
367
Gossamer Bio
GOSS
$707M
| $7.2M | 0.01% |
709,433
+104,134
| +17% | +$1.06M |
|
368
Acadia Pharmaceuticals
ACAD
$4.02B
| $7.07M | 0.01% |
167,227
+17,642
| +12% | +$745K |
|
369
FIVE9
FIVN
$1.95B
| $7.02M | 0.01% |
+91,859
| New | +$7.02M |
|
|
SWTX
370
DELISTED
SpringWorks Therapeutics
SWTX
| $6.85M | 0.01% |
253,654
+2,207
| +0.9% | +$59.6K |
|
371
Western Digital
WDC
$33B
| $6.54M | 0.01% |
207,777
+197,967
| +2,018% | +$6.23M |
|
372
BP
BP
$89.5B
| $6.51M | 0.01% |
266,756
-160,604
| -38% | -$3.92M |
|
|
SAGE
373
DELISTED
Sage Therapeutics
SAGE
| $6.25M | 0.01% |
217,667
-213,542
| -50% | -$6.13M |
|
374
Ligand Pharmaceuticals
LGND
$3.24B
| $6.25M | 0.01% |
137,694
+6,317
| +5% | +$287K |
|
|
PRAH
375
DELISTED
PRA Health Sciences, Inc.
PRAH
| $6.24M | 0.01% |
75,122
-52,604
| -41% | -$4.37M |
|